1. Home
  2. CRSP vs NOG Comparison

CRSP vs NOG Comparison

Compare CRSP & NOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • NOG
  • Stock Information
  • Founded
  • CRSP 2013
  • NOG 2006
  • Country
  • CRSP Switzerland
  • NOG United States
  • Employees
  • CRSP N/A
  • NOG N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • NOG Oil & Gas Production
  • Sector
  • CRSP Health Care
  • NOG Energy
  • Exchange
  • CRSP Nasdaq
  • NOG Nasdaq
  • Market Cap
  • CRSP 3.4B
  • NOG 3.6B
  • IPO Year
  • CRSP 2016
  • NOG N/A
  • Fundamental
  • Price
  • CRSP $37.77
  • NOG $24.19
  • Analyst Decision
  • CRSP Buy
  • NOG Buy
  • Analyst Count
  • CRSP 19
  • NOG 8
  • Target Price
  • CRSP $74.35
  • NOG $43.75
  • AVG Volume (30 Days)
  • CRSP 2.4M
  • NOG 2.2M
  • Earning Date
  • CRSP 05-07-2025
  • NOG 04-29-2025
  • Dividend Yield
  • CRSP N/A
  • NOG 7.37%
  • EPS Growth
  • CRSP N/A
  • NOG N/A
  • EPS
  • CRSP N/A
  • NOG 5.14
  • Revenue
  • CRSP $37,314,000.00
  • NOG $2,006,670,000.00
  • Revenue This Year
  • CRSP $51.35
  • NOG $14.32
  • Revenue Next Year
  • CRSP $282.16
  • NOG $7.63
  • P/E Ratio
  • CRSP N/A
  • NOG $4.71
  • Revenue Growth
  • CRSP N/A
  • NOG 14.87
  • 52 Week Low
  • CRSP $30.04
  • NOG $19.88
  • 52 Week High
  • CRSP $67.88
  • NOG $44.31
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 49.46
  • NOG 42.23
  • Support Level
  • CRSP $36.74
  • NOG $21.10
  • Resistance Level
  • CRSP $40.13
  • NOG $23.26
  • Average True Range (ATR)
  • CRSP 2.67
  • NOG 1.99
  • MACD
  • CRSP 0.72
  • NOG -0.09
  • Stochastic Oscillator
  • CRSP 76.62
  • NOG 38.83

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About NOG Northern Oil and Gas Inc.

Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. Company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), and the Appalachian Basin (Pennsylvania and Ohio).

Share on Social Networks: